Form 4 for BBNX Beta Bionics, Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2026-01-02 · accession 0002048588-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-05 | 2026-01-02 | BBNX | Feider Stephen | CFO | M - OptEx | $5.10 | +20.0K | 62.6K | +47% | +$102.0K |
| D | 2026-01-05 | 2026-01-02 | BBNX | Feider Stephen | CFO | S - Sale+OE | $29.53 | -20.0K | 42.6K | -32% | -$590.6K |
| D | 2026-01-05 | 2026-01-02 | BBNX | Feider Stephen | CFO | M - OptEx | $0.00 | -20.0K | 49.7K | -29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | M | A | 20,000 | $5.10 | 62,614 | D | — | — | |
| 2 | Common | Common Stock | 2026-01-02 | S | D | 20,000 | $29.53 | 42,614 | D | — | — | (F2) The weighted average sale price for the transaction reported was $29.534002 and the range of prices were between $29.09 and $30.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Derivative | Employee Stock Option (right to buy) | 2026-01-02 | M | D | 20,000 | $0.00 | 49,695 | D | $5.10 · — to 2033-09-13 | 20,000 Common Stock | (F3) The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. |